author-photo

Meredith Little

Takeda Pharmaceutical Company

15

Papers

575

Citations

Citation Trend

Filter By

Papers (15) Sort By

Journal Conference Others

Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician's choice in cutaneous T-cell lymphoma: final data

2021 Blood Advances
Show All
- Source
- Cite
- Save
Citations (0)
Response to brentuximab vedotin versus physician's choice by CD30 expression and large cell transformation status in patients with mycosis fungoides: An ALCANZA sub-analysis.

2021 European Journal of Cancer
Show All
- Source
- Cite
- Save
Citations (5)
SURVIVAL AMONG A PATIENT COHORT OF RELAPSED/REFRACTORY MYCOSIS FUNGOIDES IN FRANCE, GERMANY, ITALY, SPAIN AND THE UNITED KINGDOM

2019 Hematological Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial

2019 The Lancet
Show All
- Source
- Cite
- Save
Citations (254)
An Exploratory Analysis of Brentuximab Vedotin Plus CHP (A+CHP) in the Frontline Treatment of Patients with CD30+ Peripheral T-Cell Lymphomas (ECHELON-2): Impact of Consolidative Stem Cell Transplant

2019 Blood
Show All
- Source
- Cite
- Save
Citations (8)
FINAL DATA FROM THE PHASE 3 ALCANZA STUDY: BRENTUXIMAB VEDOTIN (BV) VS PHYSICIAN'S CHOICE (PC) IN PATIENTS (PTS) WITH CD30-POSITIVE (CD30+) CUTANEOUS T-CELL LYMPHOMA (CTCL)

2019 Hematological Oncology
Show All
- Source
- Cite
- Save
Citations (2)
Progression-Free Survival and Overall Survival Among a Patient Cohort of Relapsed/Refractory Mycosis Fungoides in France, Germany, Italy, Spain and the United Kingdom

2019 Blood
Show All
- Source
- Cite
- Save
Citations (0)
The ECHELON-2 Trial: Results of a Randomized, Double-Blind, Active-Controlled Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in the Frontline Treatment of Patients with CD30+ Peripheral T-Cell Lymphomas

2018 Blood
Show All
- Source
- Cite
- Save
Citations (0)
Superior Clinical Benefit of Brentuximab Vedotin in Mycosis Fungoides Versus Physician's Choice Irrespective of CD30 Level or Large Cell Transformation Status in the Phase 3 ALCANZA Study

2018 Blood
Show All
- Source
- Cite
- Save
Citations (0)
RESPONSE BY STAGE IN CD30-POSITIVE (CD30+) CUTANEOUS T CELL LYMPHOMA (CTCL) PATIENTS RECEIVING BRENTUXIMAB VEDOTIN (BV) VS PHYSICIAN'S CHOICE (PC) IN THE PHASE 3 ALCANZA STUDY

2017 Hematological Oncology
Show All
- Source
- Cite
- Save
Citations (1)